Retour
33
Également cotée sous
WILLF
OTC
Fourchette du Jour
13,45 €
14,05 €
Fourchette 52 Semaines
13,45 €
21,93 €
Volume
1
Moyenne 50J / 200J
15,24 €
/
17,81 €
Clôture Précédente
13,45 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 3,8 | 0,4 |
| P/B | 0,6 | 2,9 |
| ROE % | 15,9 | 3,9 |
| Net Margin % | 6,7 | 3,8 |
| Rev Growth 5Y % | 6,4 | 10,0 |
| D/E | 2,1 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
0,00 €
0,00 € – 0,00 €
|
27 B | 0 |
| FY2026 |
7,37 €
7,27 € – 7,63 €
|
25 B | 1 |
Points Clés
Revenue grew 6,43% annually over 5 years — modest growth
Earnings declined -35,27% over the past year
ROE of 15,92% — decent returns on equity
Debt/Equity of 2,13 — high leverage
Generating 3,18B in free cash flow
P/E of 3,84 — trading at a low valuation
Croissance
Revenue Growth (5Y)
6,43%
Revenue (1Y)2,46%
Earnings (1Y)-35,27%
FCF Growth (3Y)-5,86%
Qualité
Return on Equity
15,92%
ROIC9,51%
Net Margin6,73%
Op. Margin17,01%
Sécurité
Debt / Equity
2,13
Current Ratio1,36
Interest Coverage7,35
Valorisation
P/E Ratio
3,84
P/B Ratio0,60
EV/EBITDA6,55
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2,46% | Revenue Growth (3Y) | 1,17% |
| Earnings Growth (1Y) | -35,27% | Earnings Growth (3Y) | -7,22% |
| Revenue Growth (5Y) | 6,43% | Earnings Growth (5Y) | -11,45% |
| Profitability | |||
| Revenue (TTM) | 22,97B | Net Income (TTM) | 1,55B |
| ROE | 15,92% | ROA | 3,95% |
| Gross Margin | 75,62% | Operating Margin | 17,01% |
| Net Margin | 6,73% | Free Cash Flow (TTM) | 3,18B |
| ROIC | 9,51% | FCF Growth (3Y) | -5,86% |
| Safety | |||
| Debt / Equity | 2,13 | Current Ratio | 1,36 |
| Interest Coverage | 7,35 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 3,84 | P/B Ratio | 0,60 |
| P/S Ratio | 0,26 | PEG Ratio | -0,80 |
| EV/EBITDA | 6,55 | Dividend Yield | 0,00% |
| Market Cap | 5,93B | Enterprise Value | 25,59B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 22,97B | 22,42B | 22,44B | 19,71B | 17,91B |
| Net Income | 1,55B | 2,39B | 1,80B | 2,08B | 2,51B |
| EPS (Diluted) | 3,52 | 5,45 | 4,02 | 4,61 | 5,35 |
| Gross Profit | 17,37B | 17,09B | 16,54B | 14,67B | 13,46B |
| Operating Income | 3,91B | 4,40B | 4,15B | 3,21B | 3,66B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 39,07B | 32,45B | 30,55B | 29,86B | 24,86B |
| Total Liabilities | 29,16B | 22,81B | 21,21B | 21,30B | 16,88B |
| Shareholders' Equity | 9,84B | 9,56B | 9,26B | 8,56B | 7,98B |
| Total Debt | 20,99B | 15,68B | 14,45B | 15,08B | 11,34B |
| Cash & Equivalents | 1,33B | 1,11B | 1,14B | 1,13B | 1,17B |
| Current Assets | 10,08B | 9,92B | 9,38B | 10,02B | 7,89B |
| Current Liabilities | 7,42B | 6,10B | 6,86B | 11,57B | 10,97B |
Scores de Stratégies
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#292 of 670
Activité Récente
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026